This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System
by Zacks Equity Research
Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.
Here's Why You Should Buy Henry Schein (HSIC) Stock Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.
Is Owens & Minor (OMI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for May 17th
by Zacks Equity Research
AOSL, DIOD, LL, OMI, and RUSHA have been added to the Zacks Rank #1 (Strong Buy) List on May 17, 2021
Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic
by Zacks Equity Research
In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.
Top Ranked Growth Stocks to Buy for May 17th
by Zacks Equity Research
LL, OMI, LB, and AN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 17, 2021
Top Ranked Value Stocks to Buy for May 17th
by Zacks Equity Research
AAWW, OMI, MCBS, and SBLK made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 17, 2021
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.
Tandem (TNDM) Global Growth Strong, Costs Continue to Rise
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.
Here's Why You Should Buy Amedisys (AMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
by Zacks Equity Research
The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.
Design a Balanced Portfolio With These 5 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Vishay Intertechnology (VSH), Boise Cascade (BCC), Owens & Minor (OMI), ON Semiconductor (ON) and Sanmina (SANM) boast low P/CF ratio.
Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $33.41 in the latest trading session, marking a -2.62% move from the prior day.
Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Owens & Minor (OMI) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Owens & Minor (OMI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for May 7th
by Zacks Equity Research
CBT, OMI, ARCB, BWFG, and NVST have been added to the Zacks Rank #1 (Strong Buy) List on May 7, 2021.
6 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
National Vision (EYE) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.
GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.
Owens & Minor (OMI) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 61.86% and 1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.
DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.